medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 Lipidomics for diagnosis and prognosis of pulmonary hypertension

- 2 Natalie Bordag^{1,2,3,15}, Bence Miklos Nagy², Elmar Zügner⁴, Helga Ludwig⁵, Vasile Foris^{2,6}, Chandran
- 3 Nagaraj^{2,15}, Valentina Biasin^{2,7}, Ulrich Bodenhofer⁵, Christoph Magnes⁴, Bradley A. Maron⁸, Silvia
- 4 Ulrich⁹, Tobias J. Lange^{10,11}, Konrad Hötzenecker¹², Thomas Pieber^{3,13,15}, Horst Olschewski^{2,6,15*},
- 5 Andrea Olschewski^{2,14,15}
- 6

7 Affiliations

- 8 ¹Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
- 9 ²Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
- 10 ³CBmed GmbH, Center for Biomarker Research in Medicine, Graz, Austria.
- 11 ⁴Institute for Biomedical Research and Technologies (HEALTH), Joanneum Research
- 12 Forschungsgesellschaft m.b.H, Graz, Austria.
- 13 ⁵School of Informatics, Communications, and Media, University of Applied Sciences Upper Austria,
- 14 Hagenberg, Austria.
- ⁶Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz,
 Austria.
- ¹⁷ ⁷Division of Physiology, Otto Loewi Research Centre, Medical University of Graz, Graz, Austria.
- 18 ⁸University of Maryland School of Medicine, Baltimore, MD and The University of Maryland-Institute
- 19 for Health Computing, Bethesda, MD, USA.
- 20 ⁹Clinic of Pulmonology, University and University Hospital of Zurich, Zürich, Switzerland.
- 21 ¹⁰Department of Internal Medicine II, Pulmonology and Critical Care, Kreisklinik Bad Reichenhall,
- 22 Bad Reichenhall, Germany.
- 23 ¹¹Faculty of Medicine, University of Regensburg, Regensburg, Germany.
- 24 ¹²Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
- ²⁵ ¹³Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of
- 26 Graz, Graz Austria.
- 27 ¹⁴Experimental Anaesthesiology, Department of Anaesthesiology and Intensive Care Medicine,
- 28 Medical University of Graz, Graz, Austria.
- 29 ¹⁵BioMedTech, Graz, Austria.
- 30
- 31 *to whom correspondence should be addressed:
- 32 Prof. Horst Olschewski, Horst.Olschewski@medunigraz.at

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 Abstract

34 Background

Pulmonary hypertension (PH) poses a significant health threat with high morbidity and mortality, necessitating improved diagnostic tools for enhanced management. Current biomarkers for PH lack functionality and comprehensive diagnostic and prognostic capabilities. Therefore, there is a critical need to develop biomarkers that address these gaps in PH diagnostics and prognosis.

39 Methods

To address this need, we employed a comprehensive metabolomics analysis in 233 blood based samples coupled with machine learning analysis. For functional insights, human pulmonary arteries (PA) of idiopathic pulmonary arterial hypertension (PAH) lungs were investigated and the effect of extrinsic FFAs on human PA endothelial and smooth muscle cells was tested *in vitro*.

44 Results

PA of idiopathic PAH lungs showed lipid accumulation and altered expression of lipid
homeostasis-related genes. In PA smooth muscle cells, extrinsic FFAs caused excessive proliferation
and endothelial barrier dysfunction in PA endothelial cells, both hallmarks of PAH.

48 In the training cohort of 74 PH patients, 30 disease controls without PH, and 65 healthy controls, 49 diagnostic and prognostic markers were identified and subsequently validated in an independent cohort. Exploratory analysis showed a highly impacted metabolome in PH patients and machine learning 50 51 confirmed a high diagnostic potential. Fully explainable specific free fatty acid (FFA)/lipid-ratios were 52 derived, providing exceptional diagnostic accuracy with an area under the curve (AUC) of 0.89 in the 53 training and 0.90 in the validation cohort, outperforming machine learning results. These ratios were 54 also prognostic and complemented established clinical prognostic PAH scores (FPHR4p and 55 COMPERA2.0), significantly increasing their hazard ratios (HR) from 2.5 and 3.4 to 4.2 and 6.1, 56 respectively.

57 Conclusion

In conclusion, our research confirms the significance of lipidomic alterations in PH, introducing
 innovative diagnostic and prognostic biomarkers. These findings may have the potential to reshape PH
 management strategies.

61

62 Keywords

63 biomarker, prognosis, pulmonary hypertension, blood-based test, fatty acid to lipid ratio, lipidomics

64 Abbreviations

65 6MWD, six minute walking distance; ACh, acetylcholine; ADMA, asymmetric dimethylarginine; AUC, area under the curve; BH, Benjamini-Hochberg; BMI, body mass index; BNP 66 67 or NT-proBNP, natriuretic peptide levels; CO, cardiac output; COPD, chronic obstructive pulmonary 68 disease; CI, cardiac index; CTEPH, chronic thromboembolic pulmonary hypertension; DC, diseased 69 control (non-PH); DLCOcVA, diffusing capacity for carbon monoxide per alveolar volume, 70 hemoglobin corrected; ECAR, extracellular acidification rate; ECIS, electrical cell-substrate impedance 71 sensor; EDTA, ethylenediaminetetraacetic acid; FEV1, forced expiratory volume/1 s; FVC, forced vital 72 capacity; FFA, free fatty acids; H&E, hematoxylin-eosin; HC, healthy control; HILIC, hydrophilic 73 interaction liquid chromatography; hPAEC, human pulmonary artery endothelial cells; hPASMC, 74 human pulmonary artery smooth muscle cells; HR, hazard ratio; HRMS, high resolution mass 75 spectrometry; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; iPCA, independent principal component analysis; IVD, in vitro diagnostics; LPC, lysophosphatidylcholine; 76 77 LPE, lysophosphatidylethanolamine; LV, left ventricle; MAD, median absolute deviation; mPAP, mean 78 pulmonary arterial pressure; MS, mass spectrometry; OCR; oxygen consumption rate; OPLS-DA, 79 orthogonal projections to latent structures discriminant analysis; PA, pulmonary arteries; PAH; pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge 80 81 pressure: PBS, phosphate-buffered saline; PC, phosphatidylcholine; PDGF, platelet-derived growth 82 factor; PH, pulmonary hypertension; PPP, pentose phosphate pathway; PVR, pulmonary vascular 83 resistance; QC, pooled from samples for quality control; RAP, right atrial pressure; RDW, red cell 84 distribution width; RF, random forest; RHC, right heart catheterization; ROC, receiver operator curve; 85 RT, room temperature (20 - 25 °C); SEM, standard error of mean; SM, sphingomyelin; SMA, smooth 86 muscle actin; SvO2, mixed venous oxygen saturation; TAG, triacylglyceride; TEER, transendothelial electrical resistance; TLC, total lung capacity; VWF, von-Willebrand Factor; WHO FC, World Health 87 88 Organization functional class; WU, Wood unit; XGBoost, eXtreme Gradient Boosting;

89 Introduction

Pulmonary hypertension (PH) affects 1% of the world's population^{1,2} and thus represents a
 significant global health problem. Even mild PH is a strong negative prognosticator in patients with left
 heart disease³, lung disease⁴, and pulmonary arterial hypertension (PAH)^{5,6}.

In recent decades, global research efforts have led to targeted therapies for the rare pulmonary
 vascular diseases PAH and chronic thromboembolic PH (CTEPH). Despite this, the estimated five-year
 survival rate for newly diagnosed PAH patients has remained at only 61%^{7.8}.

Diagnosis of PH is challenging because measurement of pulmonary arterial pressure (PAP) requires right heart catheterization (RHC), whereas non-invasive methods provide only reliable estimates of PAP¹ or are not widely available⁹. Natriuretic peptide levels (BNP or NT-proBNP) are the only recommended biomarkers for PH, but they are not specific for pulmonary hypertension. Therefore, the development of new diagnostic tools for the detection of PH, risk stratification, and epidemiological studies remains an important issue².

102 Fibroproliferative remodelling of distal pulmonary arterioles drives elevation in pulmonary 103 vascular resistance and pulmonary arterial pressure. This is associated with unique metabolic changes as detected from the circulation¹⁰⁻¹⁵ as a reflection of the profound changes in the cells and matrix of 104 105 the right ventricle and pulmonary vessel walls¹⁶. Our hypothesis was that PH patients may present with a characteristic metabolic profile that allows for detection of PH and risk stratification¹. We identified 106 107 lipidomic changes in the small pulmonary arteries (PA) of IPAH patients and a unique lipidomic profile in a diverse PH cohort, allowing identification of PH among healthy and diseased controls, which was 108 confirmed in an independent validation cohort. In addition, we show that simple markers of this 109 lipidomic profile are significantly associated with survival and improve the accuracy of two established 110 111 prognostic PAH scores.

Results 112

113 Clinical and cardiopulmonary hemodynamic characteristics for the study cohorts

114 Our study included three classes of subjects: PH patients, healthy control subjects (HC) and 115 lung disease controls (DC) without PH, all of whom underwent blood-based high resolution mass 116 spectrometry (HRMS)-based metabolomics (see Fig. 1). PH patients had a mean PAP 117 $(mPAP) \ge 25 \text{ mmHg}$ and were either 1) PAH, 2) PH due to left heart disease (LV), 3) PH due to lung 118 disease, or 4) CTEPH. All DC had mPAP < 25 mmHg with either metabolic syndrome, chronic 119 obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The distributions in sex and 120 body mass index (BMI) between PH and HC/DC were similar (see Fig. 1C). Age was in the same range, 121 although controls tended to be younger. Metabolites were not significantly correlated with age (see Fig. 122 S3).



Fig. 1. Study overview for all cohorts. (A) Schematic workflow of metabolomics measurement and computational analysis. Created with BioRender.com. (B) Schematic overview of group distribution of all included patients (n = 233) in training and validation cohorts. (C) Scatter plot of BMI vs. age (shape of symbols by sex) in the training cohort with distribution histograms per PH and per HC/DC showing comparable distributions of sex and BMI in PH and HC/DC, avoiding potential confounders by design.

123 The training cohort consisted of PH patients, DC and HC, all sampled in Graz, Austria. The 124 external validation cohort contained PH patients and HC from Zürich, Switzerland and Regensburg, 125 Germany. Patient characteristics are summarized in Table 1.

127 Table 1: Patients' characteristics (medians ± 95% confidence interval)

	Т	raining (n=16	Validat	Validation (n=64)		
	HC (n=65)	HC (n=65) DC (n=30) I		HC (n=7)	PH (n=57)	
Age, years	58.0±2.8	59.5±4.7	66.5±3.0	42.0±13.8	57.0±3.7	
Female:male (ratio)	44:21 (2.1:1)	20:10 (2.0:1)	50:24 (2.1:1)	5:2 (2.5:1)	43:14 (3.1:1)	
BMI (kg/m²)	24.1±0.9	26.2±3.0	25.9±1.1	21.0±1.7	26.3±1.4	
Diagnosis (since years)	-	8±1.8	1.0±1.2	-	5.5±1.7	
Pulmonary hemodynamics	from RHC					
mPAP (mmHg) mean pulmonary arterial pressure	-	_	42.0±2.5	-	50.0±3.9	
PAWP (mmHg) pulmonary arterial wedge pressure	-	-	10.0±1.3	-	9.0±0.9	
CO (L/min) cardiac output	-	-	4.3±0.4	-	4.2±0.4	
CI (L/min/m²) cardiac index	-	-	2.6±0.2	-	2.4±0.2	
PVR (WU) pulmonary vascular resistance	-	-	7.1±1.0	-	9.1±1.7	
RAP (mmHg) right atrial pressure	-	-	6.0±1.2	-	7.5±1.1	
Clinical data						
6MWD (m) 6-min walk distance	-	454±41	330±34	-	390±31	
WHO FC world health organisation functional class	-	2.0±0.2	3.0±0.2	-	2.0±0.2	
FEV1 (% predicted) forced expiratory volume 1 s	-	51.5±9.9	75.0±5.6	-	82.2±3.0	
FVC (% predicted) forced vital capacity	-	63.8±6.7	82.8±5.5	-	91.4±4.0	
FEV1/FVC (% predicted)	-	56.3±8.5	74.4±3.0	-	75.7±2.1	
TLC (% predicted) total lung capacity	-	103.0±10.8	94.0±3.9	-	96.5±3.5	
DLCO cSB (% predicted) single-breath CO diffusing capacity, haemoglobin corrected	-	49.6±7.8	63.8±6.0	-	53.8±3.9	
DLCO cVA (% predicted) diffusing capacity for CO alveolar volume, haemoglobin corrected	-	70.0±7.9	69.6±6.1	-	62.0±3.7	
RDW (%) red cell distribution width	-	14.0±0.7	15.4±0.7	-	14.7±0.6	
NT-proBNP (pg/mL)	-	98±39	869±806	-	751±475	
Uric acid (mg/dL)	-	5.0±0.5	6.0±0.6	-	6.6±0.7	
Creatinine (mg/dL)	-	0.80±0.09	1.02±0.12	-	1.00±0.23	
Bilirubin total (mg/dL)	-	0.40±0.13	0.64±0.13	-	0.65±0.16	

128 Identification of a characteristic lipidomics profile in pulmonary hypertension

129 The metabolome of patients was assessed with untargeted hydrophilic interaction liquid chromatography (HILIC)-HRMS from serum, EDTA, and heparin plasma samples in four measurement 130 131 runs. As is typical with mass spectrometry (MS) based metabolomics methods, notable batch effects 132 occurred between runs as well as drift within the longer runs (see Fig. S2). Drift correction was 133 successfully performed (see Fig. S2) using quality control (QC) injections, which are a mix of equal 134 sample volumes repeatedly measured to monitor instrument stability.

135 In total, 164 known metabolites were of consistent analytical quality suitable for multivariate and univariate exploratory analysis. Global metabolic changes were first examined using the 136 137 unsupervised multivariate independent principal component analysis (iPCA). The metabolomes of the 138 PH patients differed from the control groups (HC and DC), which was visible as a clear group separation in the iPCA scores plot along the first component (x-axis, Fig. 2A). The observed metabolic difference 139 was strongly driven by an increase in specific free fatty acids (FFA) in PH patients (Fig. 2B). The 140 141 machine learning method orthogonal projections to latent structures discriminant analysis (OPLS-DA) 142 confirmed that the observed global metabolic differences between PH and HC/DC were significant 143 (p < 0.001, cross-validation and 1000 random permutations, Fig. 2C).



Fig. 2. PH is associated with a strong metabolic shift in the training cohort. (A) iPCA scores plot representing the metabolic profile of each subject as a dot. The proximity of the dots indicates the similarity of the subjects' metabolomes. Clear group separation by PH is visible along the first component. (B) Loadings plot corresponding to scores plot in (A). Each dot represents the contribution of the metabolite to the group separation observed in the scores plot. FFAs (yellow circles) strongly drive the group separation and are increased in PH patients. (C) OPLS-DA maximizes the group difference from PH to HC/DC and the resulting scores plot represents, as in A, the metabolome of each subject. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. The difference between the metabolome of PH and HC/DC was significant ($Q^2 > 50\%$, p< 0.001 from 1000 random permutation). (D) Volcano plot of univariate analysis showing significant ($p_{BH} < 0.05$, grev horizontal line) and strong (absolute contrast ratio > 0.25, grey vertical lines) increase in FFAs (yellow triangles). For all methods A-D, 164 known metabolites from the training cohort samples (n = 169) were used (drift corrected, log10-transformed data). Colors as in B.

144 The univariate statistical analysis confirmed that FFAs were strongly and significantly increased in PH as compared with HC/DC (Fig. 2D). The metabolites from routine clinical chemistry, 145 146 e.g. uric acid, were strongly correlated with their respective HILIC-HRMS metabolites (Fig. S3). Single

147 FFAs and lipids were not strongly correlated with any clinical parameter, suggesting that the detected

148 FFA changes may be independent from conventional clinical assessment.

149 FFA/lipid-ratios diagnose pulmonary hypertension

The potential of using our metabolites to predict PH was first investigated with the machine 150 learning method random forest (RF)^{17,18} and extreme gradient boosting (XGBoost)¹⁹. From the 164 151 metabolites, 11 were excluded from biomarker analysis because of low signal intensities and high noise 152 153 (see Supplementary Data 1). RF and XGBoost both achieved an area under the curve (AUC) of 0.82 in 154 the receiver operator curve (ROC) analysis in the validation set (Fig. 3A). The drift correction used here 155 allowed a joint exploratory statistical analysis, but drift correction is impossible in future routine clinical 156 diagnostics. Therefore, the diagnostic and prognostic performance was also tested without drift 157 correction. RF and XGBoost performance were almost identical without drift correction, indicating that their nonlinear algorithms exhibit intrinsic drift-handling capabilities (Fig. 3A). 158

159 Other important model performance parameters such as specificity, sensitivity, and balanced 160 accuracy were comparable for RF and XGBoost irrespective of drift correction. For RF and XGBoost, 161 the average balanced accuracy was 72.2% and 72.7%, respectively, the specificity was 88.6% and 162 91.2%, respectively, and the sensitivity was 55.8% and 54.1%, respectively (Fig. 3C). The validation cohort had only seven HC and no DC with a slightly different age and BMI distribution than the training 163 164 cohorts. To overcome this limitation, we tested an artificial data split into 70% training and 30% 165 validation sets with balanced distributions in age, BMI, sex and disease class (PH/DC/HC). The 166 performance of RF and XGBoost remained similar to the original split by center (Fig. S4).



Fig. 3. Diagnostic accuracy for PH in training and validation cohorts. (A) ROC plots of RF (green) and XGBoost (blue) trained with data from training cohort predicting class in validation cohort with either drift corrected, log10transformed data (left, middle) or non-drift corrected log10-transformed data (right) based on 153 metabolites. (B) The ROC plots of the three best FFA/lipid-ratios for training and validation cohort with either drift corrected, log10transformed data or log_{10} -transformed data with no drift correction (insets). (A-B) Training cohort n = 169 (solid line), validation cohort n = 64 (dashed line), ribbons mark 95% confidence intervals. (C) Plot of model performance metrics sensitivity, specificity and balanced accuracy for RF, XGBoost, and the three best FFA/lipid-ratios when based on either training (circles) or validation (diamonds) cohorts only or all available data (squares). The performance of RF and XGBoost was comparable for all three metabolite subsets with and without drift correction. The performance of the three best FFA/lipid-ratios was consistently more stable and balanced than of RF or XGBoost.

167 Despite their diagnostic potential, both machine learning approaches are not suitable for routine 168 clinical diagnostics because they are labour intensive and not fully explainable. In addition, both 169 approaches showed notable decreases in AUC, sensitivity, specificity and balanced accuracy from the 170 training to the validation cohort. Therefore, we tested whether ratios formed from lipophilic metabolites 171 with strong effects of PH versus HC/DC, normalized to metabolites with no effects of PH vs. HC/DC, 172 could replace machine learning approaches to create an explainable, easy-to-measure marker. In PH, 173 many FFAs were strongly increased while many complex lipids were unchanged (Fig. 2D), offering the 174 option to achieve markers of PH that are easy to measure. Thus, characteristic FFAs were selected into the numerator, based on their analytical performance in PH versus HC/DC and lipids with good 175 176 analytical performance and non-significance in PH vs. HC/DC were chosen for the denominator.

177 For the nominator, 11 FFA were considered: FFA C15:0 (pentadecylic acid), FFA C16:2 178 (palmitolinoleic acid), FFA C16:1 (palmitoleic acid), FFA C17:1 (heptadecenoic acid), FFA C17:0 179 (margaric acid), FFA C18:3 (α-linolenic acid, ALA, or γ-linolenic acid, GLA), FFA C18:2 (linoleic 180 acid, LA), FFA C18:1 (oleic acid), FFA C19:1 (nonadecenoic acid), FFA C20:5 (eicosapentanoic acid, 181 EPA) and FFA C20:1 (eicosenoic acid). Eight lipids, the best two from four common classes, were 182 considered for the denominator: lysophosphatidylcholine (LPC) 18:2, LPC 18:1, phosphatidylcholine 183 (PC 36:4, PC 38:6), sphingomyelin (SM 34:2, SM 36:2), lysophosphatidylethanolamine (LPE) 16:0, and LPE 18:1. To stabilize the ratios, we also tested sums of up to six FFAs in the numerator and up to 184 185 four lipids in the denominator, limiting the maximum number of individual metabolites in a given ratio 186 to ten.

187 In total, about a quarter of a million FFA/lipid-ratios were evaluated for their diagnostic performance in ROC analysis. Most FFA/lipid-ratios achieved moderate to high performance with 188 189 AUCs above 0.8 (Fig. S5A-I,K,L) irrespective of drift correction or split. There may be a concern that 190 combining multiple metabolites in a ratio increases technical error and impairs reproducibility. 191 However, in our cohort, the calculated technical variability according to the laws of error propagation 192 was <5% for most FFA/lipid-ratios and <10% for all others (Fig. S5J).

193 For simplicity, the top three ratios were selected, based on their AUC, sensitivity, and 194 specificity, and named RATIO1, RATIO2, and RATIO3 (Fig. S5M). These ratios had six metabolites 195 in common: numerator (FFA C20:1 + FFA C16:1 + FFA C15:0); denominator (PC 38:4 + PC 36:4 + 196 LPC 18:1). Compared to RATIO 1, the only difference of RATIO 2 and 3 was the addition of two more 197 FFA to the numerator sum (FFA 18:3 + FFA 17:0 and FFA 18:2 + FFA 17:0, Fig. 3B). The ROC curves 198 of RATIO1-3 overlapped well between training and validation cohort, irrespective of drift correction 199 (Fig. 3B). All other important performance parameters were also very similar between RATIO1-3 200 (Fig. 3C). As a general result, top ratios outperformed the machine learning models, irrespective of drift 201 correction or data split, especially in terms of sensitivity. The top three ratios' average balanced 202 accuracy was 85.5%, with 89.7% specificity and 81.4% sensitivity (Fig. 3C).

FFA/lipid-ratios massively reduced technical complexity compared to broad metabolomics runs while achieving better diagnostic performance than machine learning approaches. The diagnostic performance of the FFA/lipid-ratios was independent of drift correction, making them suitable for stand-alone measurements. Accordingly, we assume that FFA/lipid-ratios are suitable for future routine applications.

208 Specific FFA/lipid-ratios predict survival

The prognostic value of RATIO1 was compared with well-established prognostic PAH scores, FPHR4P²⁰ (based on WHO FC, 6MWD, RAP, and CI) and COMPERA2.0^{1,21} (based on WHO FC, 6MWD, and NT-pro-BNP). Survival and hazard ratios (HR) were investigated for all our patients with heart or lung disease and PH. For direct comparability of Kaplan-Meier survival curves and HRs, all numeric values were categorized into low or high risk according to their optimal cut-off points (e.g. 57 years for age).

215 We analysed survival times since enrolment (= baseline) which were available for 129 PH and 216 21 DC (13 COPD, 8 ILD) patients. The COMPERA2.0 score was available for 122 PH and 11 DC 217 patients, and FPHR4p for 97 patients (93 PH and 4 DC). Survival times and both scores were available 218 for 91 PH patients. As expected, FPHR4p and COMPERA2.0 scores were significantly associated with survival time (Fig. 4). RATIO1 was also significantly associated with survival (Fig. 4) with a similar 219 220 HR as COMPERA2.0 scores. When RATIO1 was combined with each of the scores (RATIO1 and 221 score equally weighted), the prognostic value of the respective score improved notably (Fig. 4). This 222 indicates that our simple metabolomic marker provided independent prognostic information and would 223 complement established prognostic scores.

As expected, established prognostic risk factors from the literature, higher WHO FC, lower 6MWD, and higher NT-proBNP were associated with poorer survival (Fig. S7). Next, we examined the major potentially confounding factors age, sex and BMI. Age > 57 yr constituted a considerable risk factor, while BMI>26.8 kg/m² and male sex were not significant (Fig. S6). Results were similar in the joint model for all three factors, suggesting that only age was a relevant confounder. Therefore, we included only age as covariate to our HR analysis (Fig. 4A).



Fig. 4. RATIO1 predicts survival and improves prediction of established clinical scores. (A) Cox HR analysis for survival from baseline without age as confounder (left side) and with age (right side, age HR shown in grey). Whiskers marks the 95% confidence intervals and statistical significance is coded as: * p < 0.05; ** p < 0.01; *** p < 0.001. Combining RATIO1 with FPHR4P or COMPERA2.0 increased HR compared with either alone. (B, C, D) Kaplan-Meier curves of survival from baseline by (B) RATIO1, (C) FPHR4p, and (D) COMPERA2.0 alone and combined with RATIO1. All cut-offs defining high or low were optimized with maxstat. RATIO1 was based on log₁₀-transformed data without drift correction. RATIO1 was combined scaled 0 to 1 with equal weighing with either each score. FPHR4p was inverted so that higher scores represent higher risk as in COMPERA2.0.

230 Overall, the HR results with age as covariate were similar to those without (Fig. 4A) and 231 although age correction caused a decrease of all HR values, their respective prognostic impact remained 232 significant.

233 Changes in lipid metabolism in pulmonary arteries of idiopathic PAH (IPAH) patients

234 We investigated small PA from IPAH patients, the prototype of PAH and healthy donor lungs 235 from explanted lungs. Oil red O staining and co-staining with markers of endothelial and smooth muscle 236 cells showed accumulation of lipids in several IPAH PA (Fig. 5A). The observed lipid deposition could 237 be the result of increased fatty acid uptake, metabolic dysregulation, or increased lipid synthesis. Therefore, we performed laser-capture microdissection of small PA (< 500 µm) from IPAH patients 238 239 and healthy donors and examined gene expression of transporters and enzymes related to lipid 240 metabolism. Gene expression showed significant upregulation of several key genes involved in lipid 241 uptake and metabolism in IPAH (Fig. 5B). Most striking was the significant upregulation of SLC27A5, 242 GAPT1, AGAPT1, Lipin2 and DGAT1. DGAT1 plays a critical role in lipid droplet formation. Up-

- 243 regulation of the FFA transport protein SLC27A5 indicates increased uptake of FFAs from the
- 244 circulation. GPAT, AGPAT, and lipin family enzymes promote triglyceride biosynthesis, incorporation
- 245 of exogenous fatty acids into triacylglycerides (TAG) and phospholipids, as well as β -oxidation. The
- 246 upregulation of these genes in the small PAs of IPAH patients might be caused by the increased
- 247 circulating FFA levels or might be a manifestation of an underlying disease mechanism.





Fig. 5. Presence of lipids and expression of lipid-metabolism genes in IPAH pulmonary arteries. (A) Visualization of endothelium (von-Willebrand factor, VWF) and smooth muscle cell layer (smooth muscle actin, SMA) together with oil red staining in human IPAH lung serial sections (scale bar: 50 µm). (B) Gene expression of lipid homeostasis-related enzymes in laser-capture microdissected human PA (n = 8-10 patients, respectively). Vertical lines represent means with standard error of mean (SEM). Asterisks mark Mann Whitney test p < 0.05. Cell organelles are adapted from Servier Medical Art (CC BY 2.0 DEED).

248 Next, we mimicked elevated circulating FFA levels by treating primary human pulmonary 249 artery smooth muscle cells (hPASMC) and human pulmonary artery endothelial cells (hPAEC) from

250 healthy donors with a FFA cocktail. Bodypi fluorescence staining showed accumulation of fat in 251 hPASMCs and hPAECs (Fig. 6A). To better understand the functional effects of this, we performed in-252 vitro studies with primary hPAEC and hPASMCs. In hPASMCs, the treatment with the FFA mixture 253 significantly promoted cell proliferation (Fig. 6B), and in hPAECs it significantly decreased 254 acetylcholine (ACh)-induced NO secretion, suggesting endothelial dysfunction (Fig. 6C). 255 We investigated the effect of the FFA mixture on endothelial barrier function by determining 256 the magnitude of thrombin-induced endothelial barrier dysfunction. Fig. 6D shows the typical response 257 of control endothelium to thrombin. When endothelial monolayers were pre-treated with FFA, they 258 exhibited a significantly pronounced decrease in transendothelial electrical resistance (TEER) and

259 delayed recovery of barrier function compared to control media (Fig. 6D). This suggests that FFA 260 treatment causes profound endothelial dysfunction. Finally, we examined FFA-induced metabolic

261 responses in hPASMCs and hPAECs by means of the Seahorse method and found significantly

262 decreased coupling efficiency in both cell types in response to FFA treatment (Fig. 6E, F). Moreover,

263 FFA exposure decreased non-mitochondrial respiration and ATP production in hPAEC and increased

264 proton leak in hPASMC. This suggests that FFA treatment changes the phenotype of hPASMCs and

265 hPAECs from healthy donors into an IPAH phenotype and that high levels of circulating FFAs may 266 cause pulmonary vascular dysfunction, representing either a primary cause or a novel vicious circle in

267 PH.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 6. Effects of FFA treatment on hPASMC and hPAEC. (A) Representative Bodipy fluorescence staining of hPASMC and hPAEC in the absence (Ctrl) or presence of extrinsic FFA (scale bar: 50 μ m). (B) Platelet-derived growth factor (PDGF)-BB induced proliferation of primary hPASMC measured with thymidine incorporation, in the absence (Ctrl) or presence of extrinsic FFA (n = 4). Changes are expressed as percentages compared with untreated controls (Ctrl). (C) ACh-induced NO production in primary hPAEC (n = 4). Changes are expressed as percentage compared with untreated controls (Ctrl). (D) TEER, as determined by electrical cell-substrate impedance sensor (ECIS), showed a significant decrease in hPAEC treated with FFA, suggesting endothelial leakage. Representative original curve (left panel) and changes expressed as percent change compared with controls (Ctrl) (n = 4). (E, F) Summarized data from hPASMC and hPAEC using the Seahorse XFe24 Extracellular Flux Analyzer. All measurements were performed on n = 25,000–50,000 cells/well and five wells per cell type. Each experimental group consisted of cell lines from two to three patients. All data were normalized to total protein per well before analysis (n = 9). Mann Whitney test * < 0.05, **< 0.01, **<< 0.001. The boxes extend from the 25th to 75th percentile, the middle line denotes the median and the whiskers mark the minimum and maximum.

269 Discussion

270 The uptake and metabolism of long-chain fatty acids is critical for many physiological and 271 cellular processes, and cellular accumulation may cause numerous pathological and functional changes. 272 Previous investigations in PAH have shown severe metabolic changes of the right ventricle and elevated in vivo myocardial triglyceride content^{10,22,23}. Our investigations add important information by showing 273 274 that small PA of IPAH patients are affected by lipid accumulation. Interestingly, we found increased 275 gene expression of enzymes causing fatty acid uptake and triglyceride biosynthesis in smooth muscle 276 cells of IPAH patients (Fig. 5C). This could be caused by the high FFA levels in the circulation, 277 however, it could also represent a change in the cell physiology that strongly contributes to the 278 development of PH.

279 For the first time, we have explored the effects of FFA exposure in primary human hPAECs 280 and hPASMCs. FFA exposure decreased NO secretion and impaired barrier function in hPAECs, and 281 caused increased proliferation in hPASMC. In addition, FFA exposure induced changes in non-282 mitochondrial respiration and coupling efficiency in both cell types. This suggests that impaired lipid 283 handling in IPAH PAs might trigger the remodelling in PAH. This is in line with numerous studies indicating that the expression of GAPT1 / AGPAT1 / lipin-1 has important metabolic consequences²⁴⁻ 284 285 ²⁷. Our data, taken in context with data from the literature, may suggest that in PH, the failing right 286 ventricle is no longer able to cope with FFA metabolism, leading to an increase in circulating FFA 287 levels, which negatively affects the pulmonary vessels. However, it is also possible that there are 288 primary changes in the lipid metabolism of the small PAs, leading to vascular dysfunction, subsequently 289 increasing right ventricular afterload, initiating a vicious circle that finally causes PH and right heart 290 failure.

Spanning over two decades, extensive basic, translational, and clinical analyses have supported 291 a causative link between metabolic reprogramming and PAH^{28,29}. Similar to the Warburg effect in 292 cancer, a shift from mitochondrial oxidation to glycolysis appears to occur in the right ventricle of PAH 293 patients^{22,23}. In this study, we show that the small PAs are affected by significant metabolic changes. 294 295 Taking cues from cancer, recent data demonstrate significant alterations in metabolic programs other 296 than glycolysis and glucose oxidation, including the pentose phosphate pathway (PPP), glutaminolysis, lipolysis, fatty acid synthesis and oxidation and changes in the plasma proteome ^{10–16,30–32}. However, it 297 298 remains unclear whether these changes originate in the overloaded right ventricle, in the primarily 299 affected pulmonary vessels, or elsewhere.

Although there has been tremendous progress in the understanding of PAH in recent decades, there is still an unmet need for diagnostics and therapy. According to a recent literature review, the fiveyear survival rate for newly diagnosed patients has not significantly improved despite a multitude of new PAH medications⁸. This may be due to the fact that the metabolic mechanisms of the disease have

304 not been addressed in detail. To our knowledge, this study is the first to apply unsupervised, broad 305 metabolome analysis of PH patients of group 1 to 4. The generated specific FFA/lipid-ratios identified patients with PH, independent of comorbidities. The same ratios provided prognostic information, 306 307 complementing existing clinical prognostic scores. The diagnostic and prognostic results were validated 308 in an independent international cohort and this was confirmed by a balanced split group approach. Of 309 note, our *in vitro* mechanistic studies suggest that disturbed lipid metabolism may significantly 310 contribute to the pathologic mechanisms in IPAH patients. Our simple FFA/lipid-ratios might be useful 311 in the diagnosis and clinical management of PH patients and might even serve as surrogate endpoints 312 in future clinical trials.

313 Classical machine learning using RF and XGboost showed that metabolic differences hold a 314 high potential for diagnostic biomarkers. Both approaches were able to overcome typical technical MS-315 specific problems such as batch effects and intensity jumps between measurements, which usually 316 require drift correction, suggesting that such labour-intensive procedures are not necessary if PH is to 317 be detected. The same is true for our easily applicable FFA/lipid-ratios that performed comparably well 318 with drift-corrected and non-corrected metabolomics data, suggesting that forming such a ratio corrects 319 for batch effects and drifts in the metabolomics dataset as well as for inter-individual variability of 320 patients' lipid metabolism and lifestyle.

321 Our FFA/lipid-ratios performed very well in both PH diagnosis and survival prediction. Their 322 diagnostic performance even outperformed RF and XGBoost models, especially in terms of sensitivity. 323 In addition, the results were stable despite the use of different sample types such as serum, heparin and 324 EDTA plasma from three different centers, a very important prerequisite for broad applicability in routine diagnostics. The performance was also stable when training and validation cohort were not split 325 326 by center but 70% to 30% balanced by age, BMI, sex and class. The FFA/lipid-ratios are easy to measure 327 and fully explainable compared to machine learning models, which is advantageous for future studies 328 and regulatory approval processes for in vitro diagnostics (IVD).

329 Survival prediction is an important tool in the management of PAH patients. Several clinical 330 scores have been established, with FPHR4P and COMPERA2.0 representing most recent developments derived from large databases^{20,21}. The FPHR4P²⁰ score estimates prognosis based on WHO FC, 6MWD, 331 CI, and RAP, while COMPERA2.0²¹ is based on non-invasive parameters, only (WHO FC, 6MWD, 332 333 NT-pro-BNP). RATIO1 showed an age-dependency that was comparable to both clinical scores. Most importantly, both clinical scores gained notably in predictive power when combined with RATIO1. 334 This suggests that FFA/lipid-ratios represent an independent, non-invasive prognostic factor that 335 336 combines favourably with established prognostic PH scores.

337 Strengths and limitations

338 Strengths of this study include exploration of primary IPAH small PA vessels, with mechanistic 339 insight in the effects of FFA on PASMC and PAEC, a broad metabolomics approach, sampling and processing conditions suitable for routine clinical practice, inclusion of a disease control group, 340 341 comprehensive clinical assessment, use of machine learning, and development of diagnostic and predictive FFA/lipid-ratios. As a limitation, we had access to a small number of patients and controls. 342 343 This may have been compensated by a profound clinical characterization of the patients, including 344 RHC, coupled with long follow-up times for survival analysis and the 70% to 30% balanced split test, 345 confirming the results. Another limitation is that FPHR4p and COMPERA2.0 have been derived from 346 PAH patients while we used them for all available patients including PH associated with left heart and 347 lung diseases. This may have introduced a bias into the prognostic performance of these scores, 348 however, this bias relates to the scores and our new markers in the same way. It may be seen as a 349 limitation, that blood samples were collected along with clinical routine blood draws, without 350 standardized fasting or other control measures, however, this may also represent a strength of our study 351 as it suggests robustness of the results. All metabolic measurements were based on high-resolution mass 352 spectrometry, a very sensitive and exact method, yet slow, expensive and work-intensive. However, our 353 FFA/lipid-ratios allow for a simplified approach that is easily available.

354 Outlook

355 Future studies including larger numbers of patients with a balanced group distribution and more 356 patients with early pulmonary hypertension and less impaired right ventricular function and longitudinal 357 studies are warranted to investigate the value of metabolic markers for patient management.

358 Conclusions

359 Based on our mechanistic insights into the metabolic changes in small PA, and our machine learning approaches, our FFA/lipid-ratios identified PH patients with a high accuracy and were 360 361 significantly associated with prognosis. This may point to novel diagnostic tools and possibly also to 362 new therapeutic targets. If implemented into the management strategy for PAH patients, this might 363 inform therapy decisions to improve outcomes of PAH therapy.

364 Supplemental Information

365 Supplemental Information can be found attached to this publication.

366 Materials Availability

367 This study did not generate new unique reagents.

368 Data and Code Availability

369 The author declare that all data supporting the findings in this study are available in the online 370 supplementary data 1 and online repositories. Mass spectrometric data have been deposited in https://zenodo.org under doi: 10.5281/zenodo.7857706. Data is provided de-identified and is available 371 372 immediately after publication with no end for those who wish to access the data for any purpose. The 373 provided Sample Name in the online supplementary data 1 links to the file names in the online 374 repository and are unsuitable to identify single patients. The primary key is only known to part of the 375 study team. Machine learning code is available immediately with no end for those who wish to access 376 for any purpose on Github: https://github.com/HelgaLudwig/PHMetab.

377 Author contributions

Conceptualisation, NB, BMN, TP, HO, AO; Data curation, NB, BMN, EZ, HL, UB, HO, AO;
Formal analysis, NB, BMN, EZ, HL, UB, HO, AO; Funding acquisition, NB, TP, HO, AO;
Investigation, NB, BMN, EZ, VF, CN, VB, HO, AO; Methodology, NB, BMN, EZ, CN, AO, HO;
Project administration, NB, BMN, UB, VF, KH, SU, TJL, HO, AO; Resources, NB, BN, EZ, CM, HL,
UB, KH; SU, TJL, TP, HO, AO; Software, NB, HL; Supervision, NB, EZ, UB, HO, AO; Validation,
NB, BN, EZ, HL, VF, CN, VB, SU, TJL, HO, AO; Visualisation, NB, BMN, HL, CN, VB, AO; Writing
– original draft, NB, BAM, HO, AO; Writing – Review & Editing, all authors;

385 Acknowledgements

We are very grateful for the excellent technical assistance from Elisabeth Blanz, Sabine
Halsegger, Daniela Kleinschek, Jessica Schweiger, Yasemin Gassner, Gert Trausinger and Edgar
Gander. We express our heartfelt gratitude to Gabor Kovacs, Saskia Trescher, Pablo López-García,
Sophie Narath, Michael Pienn and Peter Wolf for their valuable discussions and helpful advices.

390 Funding

NB, TP disclose that part of this work has been carried out with the K1 COMET Competence
Center CBmed, which is funded by the Federal Ministry of Transport, Innovation and Technology; the
Federal Ministry of Science, Research and Economy; Land Steiermark (Department 12, Business and
Innovation); the Styrian Business Promotion Agency; and the Vienna Business Agency. The COMET

program is executed by the Österreichische Forschungsförderungs GmbH FFG. VB is supported by the
 Austrian Science Foundation (FWF, T1032-B34).

397 Competing interests

Several authors (NB, CM, AO, BMN, HO) are inventors of the patent "*Biomarker for the diagnosis of pulmonary hypertension (PH)*" WO2017153472A1 (priority date 09.03.2016, granted in US, KR, JP, pending in CA, EP, AU) being jointly held by CBmed Gmbh, Joanneum Research
Forschungsgesellschaft mbH, Medical University Graz and Ludwig Boltzmann Gesellschaft GmbH.
The authors received no personal financial gain from the patent.

During work on this publication NB was partially employed at CBmed GmbH. TP is chief scientific officer (CSO) of CBmed GmbH. EZ and CM were employed at Joanneum Research Forschungsgesellschaft mbH. The employing companies provided support in the form of salaries, materials and reagents but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

408 VF received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or 409 educational events from Janssen, Chiesi, BMS, and Boehringer Ingelheim and support for attending 410 meetings, and/or travel from Janssen, MSD, and Boehringer Ingelheim outside the submitted work.

411 CN received support for attending meetings, and/or travel from Boehringer Ingelheim and412 Inventiva pharma outside the submitted work.

BAM reports personal fees from Actelion Pharmaceuticals, Tenax and Regeneron, grants from
Deerfield Company, NIH (5R01HL139613-03, R01HL163960, R01HL153502, R01HL155096-01),
Boston Biomedical Innovation Center (BBIC), Brigham IGNITE award, Cardiovascular Medical
research Education Foundation outside the submitted work. BAM reports patent PCT/US2019/059890
(pending), PCT/US2020/066886 (pending) and #9,605,047 (granted) not licensed and outside the
submitted work.

SU received grants from the Swiss National Science Foundation, Zürich and Swiss Lung
League, EMDO-Foundation, Orpha-Swiss, Janssen and MSD all unrelated to the present work. SU
received consultancy fees and travel support from Orpha-Swiss, Janssen, MSD and Novartis unrelated
to the present work.

TJL reports grants for his institution from Acceleron Pharma, Gossamer Bio, Janssen-Cilag,
and United Therapeutics; personal fees and non-financial support from Acceleron Pharma,
AstraZeneca, Boehringer Ingelheim, Gossamer Bio, Ferrer, Janssen-Cilag, MSD, Orphacare, and Pfizer
outside the submitted work.

427 KH is a consultant at Medtronic Österreich GmbH outside the submitted work.

428 TP reports grants from AstraZeneca, Novo Nordisk, Sanofi paid to the Medical University of 429 Graz outside the submitted work. TP reports personal fees and nonfinancial support from Novo Nordisk 430 and Roche Diagnostics outside the submitted work. 431 HO reports grants from Bayer, Unither, Actelion, Roche, Boehringer Ingelheim, and Pfizer. HO reports personal fees and non-financial support from Medupdate and Mondial, AOP, Astra Zeneca, 432 Bayer, Boehringer Ingelheim, Chiesi, Ferrer, Menarini, MSD, and GSK, Iqvia, Janssen, Novartis, and 433 434 Pfizer outside the submitted work. 435 AO received honoraria for presentations and support for attending meetings, and/or travel from 436 MSD outside the submitted work. No conflict of interest, financial or otherwise, are declared by the authors HL and UB. 437 438 439 440

References 441

- 442 1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and 443 treatment of pulmonary hypertension. Eur Respir J; 61. Epub ahead of print January 2023. DOI: 444 10.1183/13993003.00879-2022.
- 445 Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet 2. 446 Respir Med 2016; 4: 306-322.
- 447 3. Vachiéry J-L, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. 448 European Respiratory Journal 2019; 53: 1801897.
- 449 4. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and 450 hypoxia. Eur Respir J; 53. Epub ahead of print 2019. DOI: 10.1183/13993003.01914-2018.
- 451 5. Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in 452 patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8: 873-884. 453
- 454 6. Douschan P, Kovacs G, Avian A, et al. Mild Elevation of Pulmonary Arterial Pressure as a 455 Predictor of Mortality. Am J Respir Crit Care Med 2018; 197: 509-516.
- 456 7. Farber HW, Miller DP, Poms AD, et al. Five-Year outcomes of patients enrolled in the REVEAL 457 Registry. Chest 2015; 148: 1043-54.
- 458 8. Zelt JGE, Sugarman J, Weatherald J, et al. Mortality trends in pulmonary arterial hypertension 459 in Canada: a temporal analysis of survival per ESC/ERS guideline era. Eur Respir J; 59. Epub 460 ahead of print June 2022. DOI: 10.1183/13993003.01552-2021.
- 461 9. Kräuter C, Reiter U, Kovacs G, et al. Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI. Magn Reson Imaging 2022; 88: 132-141. 462
- Brittain EL, Talati M, Fessel JP, et al. Fatty acid metabolic defects and right ventricular 463 10. 464 lipotoxicity in human pulmonary arterial hypertension. Circulation 2016; 133: 1936–1944.
- 465 11. Hemnes AR, Luther JM, Rhodes CJ, et al. Human PAH is characterized by a pattern of lipid-466 related insulin resistance. JCI Insight; 4. Epub ahead of print 10 January 2019. DOI: 10.1172/jci.insight.123611. 467
- 468 12. Lewis GD, Ngo D, Hemnes AR, et al. Metabolic Profiling of Right Ventricular-Pulmonary 469 Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. J Am Coll 470 Cardiol 2016; 67: 174–189.
- 471 13. Rhodes CJ, Ghataorhe P, Wharton J, et al. Plasma Metabolomics Implicates Modified Transfer 472 RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. 473 *Circulation* 2017; 135: 460–475.
- 474 14. Nagy BM, Nagaraj C, Meinitzer A, et al. Importance of kynurenine in pulmonary hypertension. 475 American Journal of Physiology-Lung Cellular and Molecular Physiology 2017; 313: L741– 476 L751.
- 477 15. Nagy BM, Kovacs G, Tornyos A, et al. No indication of insulin resistance in idiopathic PAH 478 with preserved physical activity. European Respiratory Journal; 55. Epub ahead of print 1 May 479 2020. DOI: 10.1183/13993003.01228-2019.
- 480 Wertheim BM, Wang RS, Guillermier C, et al. Proline and glucose metabolic reprogramming 16. 481 supports vascular endothelial and medial biomass in pulmonary arterial hypertension. JCI 482 Insight; 8. Epub ahead of print 22 February 2023. DOI: 10.1172/jci.insight.163932.
- 483 17. Breiman L. Random forests. Mach Learn 2001; 45: 5-32.
- 484 18. Breiman L, Friedman JH (Jerome H), Olshen RA, et al. Classification and regression trees. 1st 485 ed. 1984.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 486 19. Chen T, Guestrin C. XGBoost. In: *Proceedings of the 22nd ACM SIGKDD International*487 *Conference on Knowledge Discovery and Data Mining*. New York, NY, USA: ACM, 2016, pp.
 488 785–794.
- 489 20. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline
 490 implementation in pulmonary arterial hypertension. *European Respiratory Journal*; 50. Epub
 491 ahead of print 1 August 2017. DOI: 10.1183/13993003.00889-2017.
- 492 21. Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk
 493 assessment model for pulmonary arterial hypertension. *European Respiratory Journal*; 60. Epub
 494 ahead of print 1 July 2022. DOI: 10.1183/13993003.02311-2021.
- 495 22. Talati MH, Brittain EL, Fessel JP, et al. Mechanisms of Lipid Accumulation in the Bone
 496 Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. *Am J Respir Crit Care Med*497 2016; 194: 719–28.
- 498 23. Hemnes AR, Brittain EL, Trammell AW, et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2014; 189: 325–34.
- 500 24. Bhatt-Wessel B, Jordan TW, Miller JH, et al. Role of DGAT enzymes in triacylglycerol metabolism. *Arch Biochem Biophys* 2018; 655: 1–11.
- 502 25. Chambers KT, Cooper MA, Swearingen AR, et al. Myocardial Lipin 1 knockout in mice
 503 approximates cardiac effects of human LPIN1 mutations. *JCI Insight*; 6. Epub ahead of print
 504 2021. DOI: 10.1172/jci.insight.134340.
- 505 26. Reue K. The lipin family: mutations and metabolism. *Curr Opin Lipidol* 2009; 20: 165–70.
- 50627.Takeuchi K, Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin507enzymes in triglyceride synthesis. Am J Physiol Endocrinol Metab 2009; 296: E1195-209.
- Paulin R, Michelakis ED. The Metabolic Theory of Pulmonary Arterial Hypertension. *Circ Res*2014; 115: 148–164.
- 510 29. Pi H, Xia L, Ralph DD, et al. Metabolomic Signatures Associated With Pulmonary Arterial
 511 Hypertension Outcomes. *Circ Res* 2023; 132: 254–266.
- 51230.Harbaum L, Rhodes CJ, Wharton J, et al. Mining the Plasma Proteome for Insights into the513Molecular Pathology of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2022;514205: 1449–1460.
- 51531.Rhodes CJ, Wharton J, Swietlik EM, et al. Using the Plasma Proteome for Risk Stratifying516Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2022; 205: 1102–5171111.
- Marra AM, Wei Y, Zhao H, et al. The Impact of Abnormal Lipid Metabolism on the Occurrence
 Risk of Idiopathic Pulmonary Arterial Hypertension. *International Journal of Molecular Sciences 2023, Vol 24, Page 14280* 2023; 24: 14280.
- 521
- 522
- 523

1 Online Methods

2 Cohort Data Sources

3 Results from the Graz Pulmonary Hypertension Registry (GRAPH) have been reported 4 previously^{1,2}. Briefly, the program uses a software application linked to the electronic health record for documentation of all patients of the Division of Pulmonology at the Department of Internal Medicine 5 6 of the Medical University of Graz who gave written informed consent. Demographic, clinical, 7 echocardiographic, procedural, and hemodynamic data and blood samples are collected and tracked for 8 longitudinal outcomes. All hemodynamics were measured in a standardized fashion by the same 9 experienced team¹. Regularly scheduled quality checks of the registry are performed to ensure 10 completeness and accuracy. Written informed consent was obtained from all patients and the study was 11 conducted in line with the Helsinki declaration. The study was approved by the institutional ethics board 12 (identifier: 23-408ex10/11), and the study has been registered at ClinicalTrials.gov (NCT01607502).

The BioPersMed (Biomarkers of Personalised Medicine) project is designed as a single-centre, prospective, observational cardiovascular risk study. Between 2010 and 2016, 1022 community dwelling and asymptomatic individuals were regionally recruited and assessed biannually including a standardized biospecimen acquisition³. Written informed consent was obtained from all patients and the study was conducted in line with the Helsinki declaration.

18 Cohort Study Population

We retrospectively enrolled two consecutive cohorts of patients identified through our single-center GRAPH registry and labelled them as GRAPH-Metabolomics (GRAPH-M).

The inclusion criteria for the first cohort were diagnosis of idiopathic pulmonary arterial hypertension (IPAH) and absence of severe co-morbidities. Healthy sex- and age-matched subjects served as a healthy controls (HC).

Inclusion criteria for the second cohort consisted of the following PH groups 1 – 4: 1) PAH, or 2) PH associated with heart disease, 3) PH associated with lung diseases (COPD, ILD), or 4) CTEPH. The cohort of disease controls (DC) consisted of patients with airway or parenchymal lung disease or patients with metabolic syndrome (hypertension, hypercholesterinemia and type 2 diabetes mellitus) but no signs of elevated PAP. Healthy sex- and age-matched subjects served as a control group (HC). The patients with the metabolic syndrome were selected from the BioPersMed cohort Graz.

All cohorts with the exception of patients with metabolic syndrome or HC underwent RHC. In patients who underwent multiple RHCs, the first RHC was considered the index procedure and was the only one included in the analysis. Patients were included in the analyses if data from a complete RHC were available, including a resting value for mPAP, PAWP, CO, heart rate, systolic and diastolic PA

pressure, PVR and mixed venous oxygen saturation (SvO₂). We used the standard equation to calculate
the pulmonary vascular resistance with PVR = (mPAP - PAWP)/CO expressed in WU.

36 Validation Cohort

This cohort comprised an international multicentric patient cohort. The inclusion criteria for the validation cohort were the confirmed diagnosis of PAH and informed written consent at the home institution. All participating centers were experienced centers of excellence for PH and all patients underwent RHC in a standardized manner. Demographic, clinical, echocardiographic, procedural, and hemodynamic data and blood samples were available as anonymized data. The sample collection was approved by the local Ethics Committee in each local center (Regensburg University, ethics committee No. 08/090 and cantonal ethical review board Zürich KEK 2010-0129; 2014-0214; 2017-0476).

44 Cohort Outcomes

The primary outcome was the confirmation of PH, defined as mPAP ≥ 25 mmHg according to the ERS/ESC guidelines from 2015⁴. The secondary endpoints included time to all-cause mortality with data provided by Statistic Austria (single-centre registry Graz) and by the respective centers who contributed to the validation cohort. A complete list of covariates analyzed in this study is provided in the Supplementary Material (Fig. S3).

50 Human lung tissue samples

51 Human lung tissue samples were obtained from patients with IPAH who underwent lung 52 transplantation at the Department of Surgery, Division of Thoracic Surgery, Medical University of 53 Vienna, Vienna, Austria. The protocol and tissue usage were approved by the institutional ethics 54 committee (976/2010) and written patient consent was obtained before lung transplantation. The patient 55 characteristics included: age at the time of the transplantation, weight, height, sex, mPAP measured by RHC, pulmonary function tests, as well as the medical therapy. The chest computed tomography scans 56 57 and RHC data were reviewed by experienced pathologists and pulmonologists to verify the diagnosis. 58 Healthy donor lung tissue was obtained from the same source. Donor/IPAH patient characteristics are 59 given in Supplementary Material (Table S2)Fehler! Verweisquelle konnte nicht gefunden werden..

60 Lung histological Oil Red O staining

61 The lipid accumulation of lung tissues was visualized by Oil Red O staining (Merck KGaA, 62 Darmstadt, Germany). Lung tissue was embedded in tissue freezing medium, were snap frozen at 63 -80 °C and sliced using a Leica CM 1900 cryostat (Leica Biosystems GmbH, Wetzlar, Germany) at a 64 thickness of 5 μ m per section. The slices were stained with Oil Red O working solution for 10 min, 65 differentiated in isopropanol for 5 min, and then washed with water at room temperature (20 – 25 °C) 66 (RT). The experiments were finished according to the manufacturer's instructions. The morphological

67 features of the tissues were assessed by hematoxylin-eosin (H&E) staining. The lipid in the tissue

68 observed by microscope.

69 Laser capture microdissection of PA and RNA extraction

Laser capture microdissection (LCM) of 10 donor lungs and 10 lungs from IPAH patients, as well as mRNA isolation and cDNA synthesis were performed as previously described⁵. The intima and media layers of PAs of 100 – 500 µm diameter were selected, marked and isolated with the Arcturus[®] LCM System. Captured vessels were immediately transferred into RNA lysis buffer and were snap frozen. RNeasy Micro Kit was utilized to isolate RNA (RNeasy Micro Kit, Qiagen, Hilden, Germany)⁶.

75 qRT-PCR - laser capture microdissected human PA

The expression of enzymes and transporters was analyzed with real-time quantitative (qRT)-PCR using the QuantiFast SYBR PCR reagent (Qiagen, Hilden, Germany) according to Papp et al. 2019⁷. Primer pairs (Eurofins, Graz, Austria), summarized in Supplementary Material (Table S3), were designed to span at least one exon-exon boundary to avoid the amplification of genomic DNA. The specificity of all primers, as well as the length of the amplicon, were confirmed by melting curve analysis and by running the products on 2% agarose gels, respectively.

82 Cell Isolation and culture

83 hPAECs

84 hPAECs were either purchased from Lonza or isolated from donor lungs. For the isolation of 85 donor hPAECs, PA (< 2 mm in diameter) were isolated and the endothelium incubated with an enzymatic mixture of collagenase, DNAse and dispaze in HBSS at RT⁸. Cell suspension was collected, 86 87 resuspended in VascuLife Complete SMC Medium and cultured in gelatin-coated T25 flasks at 37°C and 5% CO₂. After reaching 70 - 80% confluency, cells were trypsinized, enriched by 3 consecutive 88 89 steps of CD31-selective magnetic-activated cell sorting technology and verified via morphological and 90 marker confirmation (smooth muscle actin SMA, fibronectin, vimentin, von-Willebrand Factor VWF, 91 smooth muscle myosin heavy chain and CD31). Surplus hPAECs were frozen (endothelial cell complete 92 medium containing 12% FCS and 10% DMSO) and stored in liquid nitrogen until further use. Passages 93 2-6 were used for the experiments. Detailed patient characteristics of isolated hPAECs can be found in 94 Supplementary Material (Table S4).

95 hPASMCs

The isolation and culture of human hPASMCs was performed as previously reported⁹. After the removal of the endothelial cell layer, the media was peeled away from the underlying adventitial layer and cut into approximately 1–2 mm² sections, centrifuged and resuspended in VascuLife Complete

99 SMC Medium supplemented with 20% FCS and 0.2% antibiotics, then transferred to T75 flasks and 100 cultured at 37°C and 5% CO₂. After confluency of hPASMC was formed, the cells were trypsinized and either cultured in VascuLife Complete SMC medium supplemented with 10% FCS and 0.2% 101 102 antibiotics, or frozen (VascuLife Complete SMC Medium containing 15% FCS and 10% DMSO) and 103 stored in liquid nitrogen until further use. Passages 4-8 were used for the experiments. SMCs were 104 verified via morphological and marker confirmation (smooth muscle actin SMA, fibronectin, vimentin, 105 von-Willebrand Factor VWF, smooth muscle myosin heavy chain and CD31). Detailed patient 106 characteristics of isolated hPASMCs can be found in Supplementary Material (Table S4).

107 Lipid visualized by bodipy staining

108 BODIPY (D3922, Invitrogen, Carlsbad, Calif, USA) (excitation wavelength 493 nm, emission maximum 503 nm), was diluted in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 12 109 mM HPO₄²⁻/H₂PO₄⁻, pH 7.4) or DMSO at a concentration of 1 mg/mL and applied to the hPASMCs 110 111 and hPAECs for 20 mins at RT. Fixed cells (4% paraformaldehyde at 37°C for 5 mins) were used. 112 Following fixation, samples were washed 3 times in PBS for 10 min. Sections were counterstained with 113 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) to visualize nuclei and covered 114 with glass cover slips. Images were taken using a laser scanning confocal microscope (Zeiss LMS 510 115 META; Zeiss, Jena, Germany) with Plan-Neofluar (×40/1.3 Oil DIC) objective.

116 Measuring cell metabolic state

117 Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined by the Seahorse XFp analyzer (Agilent, USA)¹⁰. hPASMCs or hPAECs were plated onto cell culture 118 119 microplates on the day before the experiments and treated with 0.25mM FFA (a mix of oleate, FFA 120 16:0 and FFA C18 (2:1:1)) in VascuLife® complete Medium and incubated for 24 h. Cells were then 121 incubated in XF assay medium (Agilent), supplemented with 25 mmol/L glucose and 1 mmol/L pyruvate (hPASMCs) or 10 mmol/L glucose, 1 mmol/L pyruvate, and 2 mmol/L L-glutamine (hPAECs) 122 123 for 1 h at RT before the measurement. After the recording of the basal rates of OCR and ECAR, final concentrations of 1 µmol/L oligomycin, 1 µmol/L carbonyl cyanide-4 (trifluoromethoxy) 124 125 phenylhydrazone, and 0.5 µmol/L rotenone and antimycin A for human hPASMCs; 1 µmol/L 126 oligomycin, 1 µmol/L carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone, and 1 µmol/L rotenone 127 and antimycin A for human hPAECs were added (XF Cell Mito Stress Test Kit, Agilent) through the 128 instrument's injection ports to obtain proton leak, maximal respiratory capacity, and nonmitochondrial 129 respiration, respectively. Glycolytic capacity was measured using an XF Glycolysis Stress Test Kit 130 (Seahorse Bioscience). ECAR was determined after serial injection with 10 mmol/L D-glucose, 1 131 µmol/L oligomycin, and 100 mmol/L 2-deoxyglucose. All the assays were performed in triplicate and 132 normalized to protein content.

133 **Endothelial Barrier Function**

134 TEER served as an indicator of barrier function of endothelial cell monolayers. TEER was determined using an electrical cell-substrate impedance sensor (ECIS) (Applied Biophysics, Troy, NY, 135 136 USA). Briefly, the endothelial cells are seeded in complete medium into (8W10E -PET arrays Applied 137 Biophysics, NY, USA) each well and allowed them to grow until they reached confluence. The FFA 138 (0.25 mM, a combination of FFA 18:1, FFA 16:0 and FFA 18:0 (2:1:1)) was applied for 24 hours before 139 the barrier disruption was initiated by addition of recombinant human thrombin.

140 Proliferation

141 To investigate the proliferative effect of FFA treatment on hPASMCs, the following protocol 142 was applied¹¹: 10 000 hPASMCs were seeded in 96-well plates; the following day the cells were starved (VascuLife® Basal Medium, 0% FCS, 0.2% antibiotic/antimycotic) or kept under control conditions 143 144 (VascuLife® Basal Medium with 5% FCS; LifeLine Technology, Walkersville) for 12 h. Afterwards, 145 platelet-derived growth factor (PDGF)-BB was added and the proliferation of hPASMCs was 146 determined by [3H] thymidine (BIOTREND Chemikalien GmbH) incorporation, after 24 h of 147 incubation, as an index of DNA synthesis and measured as radioactivity by scintillation counting 148 (Wallac 1450 MicroBeta TriLux Liquid Scintillation Counter and Luminometer). To investigate the 149 effect of FFA (0.25 mM, a combination of oleate, FFA 16:0 and FFA 18:0 (2:1:1)) on hPASMCs, the same number of cells was seeded and after 12 h of starvation, FFA and vehicle were added and the 150 151 proliferation of hPASMCs was determined as aforementioned. All experiments were performed in 152 quadruplicate.

153 **DAF-DM-mediated nitric oxide measurement**

154 Measurements were performed as previously described⁸. hPAECs were seeded in gelatincoated dark 96-well plates, starved for 2 h with Ringer's solution and loaded with 10 µm 4-Amino-5-155 Methylamino-2',7'-Difluorofluorescein Diacetate (DAF-FM) for 30 min at 37°C. The cells were 156 157 stimulated with 5 µM acetylcholine (ACh) for the induction of nitric oxide measurement on 158 CLARIOstar Plus (BMG Labtech, Ortenberg, Germany) at Ex/Em = 495/515 nm. All the assays were 159 performed in quadruplicate and normalized to protein content.

160 Plasma liquid chromatography-mass spectrometry metabolomics

161 Metabolites were analysed by targeted hydrophilic interaction liquid chromatography-high resolution mass spectrometry (HILIC-HRMS) metabolomics according to Bajad et al.¹² and samples 162 were processed according to Yuan et al.¹³ as described previously^{14,15}. 163

164 Samples from Graz were aliquoted and stored at the Biobank Graz. On the day of the processing they were thawed in water ice bath on a slow rotary shaker (300 rpm) in < 10 min and vortexed shortly. 165

Aliquots of 100 µl were precipitated in LoBind Eppendorf tubes with 400 µl cold methanol (-80°C for 166 167 at least 4 h, kept on dry ice) and vortexed shortly. After the overnight precipitation at -80 °C the samples were centrifuged for 10 min at 14.000 g at 4°C and supernatants transferred to fresh LoBind Eppendorf 168 169 tubes. Supernatants were dried under nitrogen flow and stored at -80°C until all batches of the cohort 170 were finished. Extracts were reconstituted in 100 µl 30% methanol/H₂O, vortexed for 45 s and 171 centrifuged for 5 min at 14.000 g at 4°C. The supernatant was transferred into autosampler vials, and 172 equal aliquots from all samples were pooled for quality control (QC). All ready-to-measure extracts 173 were refrozen at -80°C prior to measurement. Every 24 h samples were freshly thawed at RT, vortexed, 174 spun down and added to the autosampler at 4°C.

Measurements were made in independent runs per cohort with samples in randomized order, interspaced by according blanks, pooled QC samples and UltimateMix (UM, described previously¹⁶). Pooled QC samples were generated independently for cohort 1 and 2, while QC was mixed for cohort 3 and 4. Cohorts 1 and 2 were extracted and measured in 1 batch, while cohorts 3 and 4 were randomly divided into 6 batches for sample extraction and measured with daily thawed extracts to reduce metabolite degradation.

Extracts were measured with a Dionex Ultimate 3000 high-performance liquid chromatography (HPLC) setup (Thermo Fisher Scientific, USA) equipped with a NH₂-Luna HILIC analytical column and crudcatcher with an injection volume of 10 μ l and a 37 min gradient from aqueous acetonitrile solution [(5% acetonitrile v/v), 20 mM ammonium acetate, 20 mM ammonium hydroxide, pH 9.45] as eluent A (LMA) to acetonitrile as eluent B (LMB). Mass spectrometric detection was carried out with a Q-ExactiveTM system (Thermo Fisher Scientific). Electrospray ionization (ESI) was used for negative and positive ionization and masses between 70 and 1050 m/z were detected.

188 Raw data were converted to mzXML using msConvert (ProteoWizard Toolkit v3.0.5), and 189 target metabolites were extracted using the in-house developed tool PeakScout. Spectrum slices were 190 presented around the exact target mass (\pm 50 ppm) and retention time (\pm 3 min) in accordance with the 191 standards described by Sumner et al.¹⁷. For each target metabolite all peak area integrations were 192 manually confirmed in each sample. Molecular masses of target metabolites were taken from literature and available online databases (HMDB, KEGG, Metlin)¹⁸⁻²⁰. In addition, pure substances of all 193 194 hydrophilic metabolites and selected lipophilic metabolites were run on the same system to obtain 195 accurate reference retention times and fragmentation spectra.

196The analytical quality of all targeted metabolites was strictly graded to be suitable for197multivariate analysis and univariate analysis using the following parameters: deviation from target mass198< 5 ppm, mass difference range < 10 ppm, retention time standard deviation < 0.75 min, percentage of</td>199missing values < 30%, relative standard deviation in QC after drift correction <30%, and blank load in</td>200QC < 30%. Of 164 included metabolites, 11 metabolites were considered unsuitable for ROC analysis</td>

201 due to lower signal intensity and lower consistency in repeated sample measurements (controls in 202 cohorts 3 and 4).

Analytical quality of samples, blanks, QC, and UM was graded by sample median, peak shapes, retention time shifts, percentage of missing values < 30%, and position in the PCA scores plot. From cohort 2, the first two UM and from cohort 4 the last four QC did not meet the quality criteria and were therefore excluded.

207 Statistical analysis

Data visualisation and statistical analysis were performed with R v4.0.2 (R Core Team, 2020) (using the packages readxl, openxlsx, stringr, dplyr, tidyr, doParallel, statTarget, car, colorspace, RColorBrewer, ggplot2, ggforce, ggpmisc, ggpubr, scales, grid, ellipse, correlation, dendsort, pheatmap, nlme, emmeans, missMDA, FactoMineR, mixOmics, MetaboAnalystR 3.0.3, survival, survminer, pROC, caret, patchwork) and TIBCO Spotfire v12.5.0 (TIBCO, Palo Alto, CA). Graphpad Prism v9 has been used to assess differences in the *in vitro* experiments.

214 Typically, MS results are relative and only comparable within the same run. However, recent 215 advances in drift correction allow to merge data for joint analysis. Peak areas without drift correction 216 were log_{10} -transformed prior to all further analysis. The drift correction was based on the RF driven 217 algorithm that used OC measurements to model batch effects and drift for each metabolite with statTarget::shiftCor(., Frule = 0.7, ntree = 500, impute = "KNN", coCV = 100, QCspan = 0, degree 218 $= 2)^{21}$. The imputed, drift-corrected data were multiplied by 10^3 to make the numbers more readable 219 220 after log_{10} -transformation. In the drift corrected, log_{10} -transformed data all imputed values were removed and data was trimmed by median absolute deviation (MAD) score²², assuming a normal 221 222 distribution (multiplication with 1.4826). Strong single outliers were removed with a very conservative 223 threshold of having an absolute MAD score > 4 (165 single values in 65 metabolites). Data for all 224 metabolites and samples is provided in Supplementary Data 1 with and without drift correction.

225 In order to ensure validity of drift correction and subsequent results, each measurement run was 226 first analysed independently with unsupervised multivariate (iPCA), supervised multivariate (OPLS-227 DA) and univariate on log₁₀-transformed data without drift correction (see Fig. S1). Next, drift 228 corrected, log₁₀-transformed data from all runs was jointly analysed with the same methods. The drift 229 correction successfully removed the significant difference between measurement runs and notably 230 reduced the technical variability in all metabolites (Fig. S2). Additionally, no difference was observed 231 based on center or sample material type (Fig. S2). Replicate measurements of samples in different runs 232 were average on drift corrected data to yield one metabolome per patient for subsequent analysis one 233 metabolome per patient.

234 All reported p-values were adjusted for multiple testing according to Benjamini-Hochberg 235 (BH) denoted as p_{BH} (*stats::p.adjust()*)²³. Distribution and scedasticity were investigated with 236 Kolmogorov-Smirnov test (stats::ks.test()) and Brown–Forsythe Levene-type test 237 (car::leveneTest())²⁴, respectively. After log₁₀-transformation data was mostly normally distributed with 91% of all metabolites without drift correction and 99% of all metabolites with drift correction 238 239 testing not significant ($p_{BH} > 0.05$). Analog, data was mostly homoscedastic with 79% without drift 240 correction and 80% with drift correction of all metabolites testing not significant ($p_{BH} > 0.05$).

For iPCA missing values were imputed with *missMDA*::*imputePCA(., ncp* = $10)^{25}$ and analysis 241 was performed scaled and centred to unit variance (z-scaled) with mixOmics::ipca(., scale = TRUE). 242 243 $ncomp = 2, mode = "deflation")^{26}.$

244 For OPLS-DA missing values were imputed with MetaboAnalystR::ImputeMissingVar(., *method* = "knn var")²⁷, data was scaled and centred to unit variance (z-scaled) with 245 and 246 MetaboAnalystR::Normalization(..., *"AutoNorm"*) models calculated were with MetaboAnalystR:: OPLSR.Anal(., reg = TRUE) with a standard 7-fold cross-validation for the factor 247 248 disease. Model stability was additionally verified with 1000 random label permutations by 249 MetaboAnalystR::OPLSDA.Permut(., num = 1000).

250 Pearson correlation were calculated for each metabolite (drift corrected, *log*₁₀-transformed data) 251 against each numeric clinical parameter (untransformed) with *correlation::correlation()*²⁸. Results were filtered to retain only metabolites and clinical parameters with at least one significant correlation 252 253 $(p_{BH} < 0.05)$. Retained correlations were clustered by Lance-Williams dissimilarity update with 254 complete linkage using stats::dist() and stats::hclust(). Dendogram were sorted with dendsort::dendsort()²⁹ at every merging point according to the average distance of subtrees and plotted 255 256 at the corresponding heat maps of Pearson R with *pheatmap*::*pheatmap*()³⁰.

For univariate analysis of significant changes within each metabolite for the factor disease (i.e. 257 PH vs. HC/DC) generalized least squares models were fitted with $nlme::gls()^{31,32}$ without confounders 258 and with potential confounders (age, sex, BMI) by maximum likelihood. For analysis within each cohort 259 260 log10-transformed data was used, for joint analysis over all cohorts drift corrected, log10-transformed 261 data was used, thus constituting a nonlinear approach. The three most common potential confounders 262 (age, sex, BMI) were added stepwise in all possible combinations and model performances were 263 compared within each metabolite by lower AIC (Akaike information criterion; relative estimate of 264 information loss), higher log-likelihood (goodness of fit), significance in log-likelihood ratio test comparing two models, quality of Q-Q plots, randomness in residual and direct comparison of t-ratios. 265 266 All models with any confounder combination showed significant influence (p < 0.01) on selected few 267 metabolites (13-39). The model with age + sex impacted most metabolites. However, a direct

comparison of t-ratio revealed a very small impact of age or sex correction on results, and according to
 model parsimony models without confounders were reported throughout.

270 FFA/lipid-ratios were calculated with FFAs in the numerator and lipids in the denominator. The 271 numerators were all possible, summed (not weighed) combinations of up to six FFA from 11 FFAs 272 (most significant in univariate analysis PH versus HC/DC and best analytical quality): FFA C15:0, FFA C16:2, FFA C16:1, FFA C17:1, FFA C17:0, FFA C18:3, FFA C18:2, FFA C18:1, FFA C19:1, 273 274 FFA C20:5 and FFA C20:1. The denominators were all possible, summed (not weighed) combinations 275 of up to four lipids from eight lipids (no significant change in univariate analysis and best analytical guality): LPC 18:2, LPC 18:1, PC 36:4, PC 38:6, SM 34:2, SM 36:2, LPE 16:0, and LPE 18:1. The 276 277 combination of all possible summed FFA numerator and summed lipid denominator yielded a total of 278 240 570 different FFA/lipid-ratios. All used FFA and lipids had no missing values. The technical 279 variability RSD in QC was calculated for each FFA/lipid-ratio following the rules of error propagation 280 from the single metabolites RSD of QC in drift corrected, log₁₀-transformed data. All FFA/lipid-ratios 281 were calculated once without and once with drift correction (both log₁₀-transformed). Diagnostic 282 performance was tested by ROC analysis with $pROC::roc(..., algorithm = 2)^{33}$ based on our training cohort. Test data like in machine learning approaches was not needed here because ratios are directly 283 284 calculated without any model training. Therefore logistic regression was performed fitting training data with stats::glm(..., family = "binomial"). The performance was evaluated on the validation cohort 285 286 using pROC::roc(). The optimal threshold was determined with pROC::coords(..., best.method =287 "closest.topleft") to determine sensitivity and specificity.

288 Survival analysis used either times since sampling or times since diagnosis defining confirmed 289 death as endpoint while censoring all others at time of last known follow-up. Impact of all relevant 290 clinical parameters (untransformed), all single metabolites (drift corrected, log₁₀-transformed data) and 291 best performing FFA/lipid-ratios (log₁₀-transformed data without drift correction) was analysed. 292 FPHR4p scores were inverted so that higher values represent higher mortality risk. Numerical parameters were split into high and low with maxstat as optimal cut-off for survival prediction as 293 determined by survminer::surv cutpoint(..., minprop = 0.3)³⁴. Kaplan-Meier curves were fitted for 294 each category with *survival::survfit()*³⁵, differences were tested with *survminer::ggsurvplot()* and plots 295 with time since diagnosis were truncated at 15 years for better comparability with times since baseline 296 (i.e. time since sampling). The Cox HR analysis³⁶ was calculated with *survminer::coxph()* for the 297 298 confounders (age, sex, BMI), the COMPERA 2.0 score, FPHR4p, and RATIO1 alone or in 299 combinations. Numeric factors were categorized into high and low same as for Kaplan-Meier curves. 300 The combination of RATIO1 with the FPHR4p or COMPERA 2.0 score was done additively with the 301 same weighting on scaled values from 0 to 1, rescaling after addition.

302 Data visualisation and calculation of the machine learning and Cox 303 HR analysis was performed with Python 3.9 (using the packages pandas, numpy, seaborn, sklearn, 304 matplotlib, xgboost)³⁷⁻⁴⁰.

For machine learning, the package sklearn⁴¹ was used for the random forest (RF) and package 305 xgboost for the XGBoost⁴² implementation, for better reproducibility a fixed random seed was set. Data 306 was normalized with mean 0 and variance 1. A hyperparameter search for number of trees {101, 301, 307 308 309 200, 300} and n estimators {101, 301, 1001, 2001, 3001} for XGBoost was conducted with finally used 310 hyperparameters highlighted in bold. Models were trained on training cohort data, which was randomly 311 further divided five times into 80% for training and 20% for testing (stratified by class, age, sex, with 312 non-overlapping test data). Trained models were validated with the external validation cohort, which 313 had no data overlap with the training cohort.

Additionally to the original split by center (i.e. city of sample origin), all samples were artificially split into 70% training and 30% validation sets with balanced distributions in age, BMI, sex and class (PH/DC/HC) to overcome the potential bias from the unequal distribution of age, BMI, sex and class in the original training and validation cohorts by center. The distribution of age and BMI was equal according to a t-test as well as for sex and class (PH/HC/DC) according to a χ^2 test (p > 0.2). All machine learning and FFA/lipid-ratio ROC analysis were repeated for these 70:30 training and validation sets.

321 Language editing was aided by the artificial intelligence tool <u>https://instatext.io/</u> (last accessed
322 November 2023).

- 323
- 324

Online References 326

- 327 1. Kovacs G, Avian A, Wutte N, et al. Changes in pulmonary exercise haemodynamics in 328 scleroderma: a 4-year prospective study. Eur Respir J; 50. Epub ahead of print 2017. DOI: 329 10.1183/13993003.01708-2016.
- 330 Kovacs G, Avian A, Bachmaier G, et al. Severe Pulmonary Hypertension in COPD: Impact on 2. 331 Survival and Diagnostic Approach. Chest 2022; 162: 202-212.
- 332 3. Haudum CW, Kolesnik E, Colantonio C, et al. Cohort profile: 'Biomarkers of Personalised 333 Medicine' (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria 334 to evaluate novel biomarkers in cardiovascular and metabolic diseases. BMJ Open 2022; 12: 335 e058890.
- 336 4. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and 337 treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of 338 Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European 339 Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital 340 Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur 341 Respir J 2015; 46: 903-75.
- 342 5. Hoffmann J, Wilhelm J, Marsh LM, et al. Distinct differences in gene expression patterns in 343 pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic 344 pulmonary fibrosis with pulmonary hypertension. Am J Respir Crit Care Med 2014; 190: 98-345 111.
- 346 6. Nagaraj C, Tabeling C, Nagy BM, et al. Hypoxic vascular response and ventilation/perfusion 347 matching in end-stage COPD may depend on p22phox. Eur Respir J; 50. Epub ahead of print 1 348 July 2017. DOI: 10.1183/13993003.01651-2016.
- 349 7. Papp R, Nagaraj C, Zabini D, et al. Targeting TMEM16A to reverse vasoconstriction and 350 remodelling in idiopathic pulmonary arterial hypertension. Eur Respir J; 53. Epub ahead of print 351 1 June 2019. DOI: 10.1183/13993003.00965-2018.
- 352 8. Skofic Maurer D, Zabini D, Nagaraj C, et al. Endothelial Dysfunction Following Enhanced 353 TMEM16A Activity in Human Pulmonary Arteries. Cells; 9. Epub ahead of print 28 August 354 2020. DOI: 10.3390/CELLS9091984.
- 355 9. Stulnig G, Frisch MT, Crnkovic S, et al. Docosahexaenoic acid (DHA)-induced heme 356 oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells. 357 Atherosclerosis 2013; 230: 406–413.
- 358 10. Kikuchi N, Satoh K, Kurosawa R, et al. Selenoprotein P Promotes the Development of 359 Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target. Circulation 2018; 138: 360 600-623.
- 361 11. Biasin V, Marsh LM, Egemnazarov B, et al. Meprin β, a novel mediator of vascular remodelling 362 underlying pulmonary hypertension. J Pathol 2014; 233: 7-17.
- 363 12. Bajad SU, Lu W, Kimball EH, et al. Separation and quantitation of water soluble cellular 364 metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J 365 Chromatogr A 2006; 1125: 76-88.
- 366 13. Yuan M, Breitkopf SB, Yang X, et al. A positive/negative ion-switching, targeted mass 367 spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. 368 Nat Protoc 2012; 7: 872-81.
- 369 14. Fröhlich EE, Farzi A, Mayerhofer R, et al. Cognitive impairment by antibiotic-induced gut 370 dysbiosis: Analysis of gut microbiota-brain communication. Brain Behav Immun 2016; 56: 140-371 155.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 372 15. Mueller KM, Hartmann K, Kaltenecker D, et al. Adipocyte Glucocorticoid Receptor Deficiency 373 Attenuates Aging- and Hfd-Induced Obesity, and Impairs the Feeding-Fasting Transition. 374 Diabetes 2017; 66: 272-286.
- 375 16. Vogel FCE, Bordag N, Zügner E, et al. Targeting the H3K4 Demethylase KDM5B Reprograms 376 the Metabolome and Phenotype of Melanoma Cells. Journal of Investigative Dermatology 2019; 377 139: 2506-2516.e10.
- 378 Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical 17. 379 analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). 380 Metabolomics 2007; 3: 211–221.
- 381 18. Guijas C, Montenegro-Burke JR, Domingo-Almenara X, et al. METLIN: A Technology 382 Platform for Identifying Knowns and Unknowns. Anal Chem 2018; 90: 3156.
- 383 19. Kanehisa M, Sato Y, Kawashima M, et al. KEGG as a reference resource for gene and protein 384 annotation. Nucleic Acids Res 2016; 44: D457–D462.
- 385 20. Wishart DS, Feunang YD, Marcu A, et al. HMDB 4.0: The human metabolome database for 386 2018. Nucleic Acids Res 2018; 46: D608–D617.
- 387 21. Luan H, Ji F, Chen Y, et al. statTarget: A streamlined tool for signal drift correction and interpretations of quantitative mass spectrometry-based omics data. Anal Chim Acta 2018; 1036: 388 389 66-72.
- 390 22. Leys C, Ley C, Klein O, et al. Journal of Experimental Social Psychology Detecting outliers : 391 Do not use standard deviation around the mean, use absolute deviation around the median. 392 Experimental Social Psychology 2013; 4–6.
- 393 23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful 394 Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B 395 (Methodological) 1995; 57: 289-300.
- 396 24. Brown MB, Forsythe AB. Robust Tests for the Equality of Variances. J Am Stat Assoc 1974; 397 69: 364.
- 398 Husson F, Josse J. missMDA: Handling Missing Values with Multivariate Data Analysis. R 25. 399 package version 1.8.2., http://cran.r-project.org/package=missMDA (2015).
- 400 26. Rohart F, Gautier B, Singh A, et al. mixOmics: An R package for 'omics feature selection and 401 multiple data integration. PLoS Comput Biol 2017; 13: e1005752.
- 402 27. Pang Z, Chong J, Li S, et al. MetaboAnalystR 3.0: Toward an Optimized Workflow for Global 403 Metabolomics. Metabolites 2020; 10: 186.
- 404 28. Makowski D, Ben-Shachar M, Patil I, et al. Methods and Algorithms for Correlation Analysis 405 in R. J Open Source Softw 2020; 5: 2306.
- 406 29. Sakai R, Biederstedt E. dendsort: modular leaf ordering methods for dendrogram representations 407 in R. Epub ahead of print 2021. DOI: 10.12688/f1000research.4784.1.
- 408 30. Kolde R. pheatmap: Pretty Heatmaps. R package version 1.0.12, https://CRAN.R-409 project.org/package=pheatmap (2019, accessed 13 February 2023).
- 410 31. Pinheiro J, Bates D, R Core Team. nlme: Linear and Nonlinear Mixed Effects Models, 411 https://CRAN.R-project.org/package=nlme (2022, accessed 13 February 2023).
- 412 32. Pinheiro J, Bates D, DebRoy S, et al. nlme: Linear and Nonlinear Mixed Effects Models. R 413 package version 3.1-122 2015; 3: 57.
- 414 Robin X, Turck N, Hainard A, et al. pROC: An open-source package for R and S+ to analyze 33. 415 and compare ROC curves. BMC Bioinformatics 2011; 12: 77.
- Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using 'ggplot2', 416 34. 417 https://CRAN.R-project.org/package=survminer (2021, accessed 13 February 2023).

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 418 35. Therneau TM. Package for Survival Analysis in R, https://CRAN.R-419 project.org/package=survival (2021, accessed 13 February 2023).
- 420 36. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society: Series B*421 (*Methodological*) 1972; 34: 187–202.
- 422 37. Harris CR, Millman KJ, van der Walt SJ, et al. Array programming with NumPy. *Nature* 2020;
 423 585: 357–362.
- 424 38. McKinney W. Data Structures for Statistical Computing in Python. In: *PROC. OF THE 9th* 425 *PYTHON IN SCIENCE CONF. (SCIPY 2010).* 2010, pp. 56–61.
- 426 39. Waskom M, Botvinnik O, O'Kane D, et al. mwaskom/seaborn: v0.8.1 (September 2017). Epub
 427 ahead of print 2017. DOI: 10.5281/zenodo.883859.
- 428 40. Hunter JD. Matplotlib: A 2D Graphics Environment. *Comput Sci Eng* 2007; 9: 90–95.
- 429 41. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in Python.
 430 Journal of Machine Learning Research 2011; 12: 2825–2830.
- 431 42. Chen T, Guestrin C. XGBoost. In: *Proceedings of the 22nd ACM SIGKDD International*432 *Conference on Knowledge Discovery and Data Mining*. New York, NY, USA: ACM, 2016, pp.
 433 785–794.
- 434
- 435

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

437 Supplementary Figures



Fig. S1. PH is associated with a strong metabolic shift in every measurement run. (A) iPCA scores plot representing the metabolic profile of each sample as a dot. The proximity of the dots indicates the similarity of the subjects' metabolomes. Clear group separation by PH is visible along the first and or second component for each run and when all runs are jointly analyzed. (B) To A corresponding loadings plot in which each dot represents the contribution of the metabolite to the group separation observed in the scores plot. Free fatty acids (FFA, yellow circles) strongly drive the group separation and are increased in PH patients. (C) OPLS-DA maximizes the group difference from PH to HC/DC and the resulting scores plot represents, as in A, with dots the metabolome of each subjects. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. The difference between the metabolome of PH and HC/DC was significant ($Q^2 > 50\%$, p < 0.001). (D) Volcano plot of univariate analysis highlighting significant ($p_{BH} < 0.05$, grey horizontal line) and strong (absolute contrast ratio > 0.25, grey vertical lines) increase in FFAs. For all methods 164 known metabolites and all samples from the measurement run per cohort ($n_1 = 16$, $n_2 = 33$, $n_3 = 118$, $n_4 = 109$) on *log10*-transformed was used. In run 4 measurement all HC samples from run 3 were repeated to evaluate reproducibility of samples across measurement runs.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. S2. Drift correction improves data quality enabling a unified analysis of all 4 measurement runs. (A, B) Plot of the sample's median signal intensity of all metabolites versus the sequence of measurement with measurements runs being separated by vertical black lines. (A) The QC samples (grey x) fluctuate within each measurement (= drift), while the batch effect is well visible as signal intensity jumps between the measurements. (B) Drift correction with an RF-based algorithm on OC samples removed drift and batch effects from the median sample intensity. (C, E, G, H, I, J) iPCA scores plots plot representing the metabolic profile of each sample as a dot. The proximity of the dots indicates the similarity of the metabolomes. Lines connect replicate measurements from same samples. Note (C, G, H) are the same iPCA model highlighting different biological factors. Analog (E, I, J) are the same iPCA model. (C) A clear group separation by measurement run is well visible between all 4 runs, with runs 3 and 4 being more similar due to the back to back measurement and shared HC and QC samples. (D) Drift correction removes the separation by measurement run. (D, F) OPLS-DA maximizes the differences between runs 1 to 4 and the resulting scores plot represents, as in C, with dots the metabolome of each sample. Similarly, proximity indicates similarity and ellipses mark the 95% confidence interval of the groups. (D) All 4 measurement runs were highly significantly ($Q^2 > 50\%$, p < 0.001) different before drift correction and (F) become non-significant after drift correction. (G, I) The observed group separation by sample origin (study center) before drift correction was significantly reduced after drift correction. (H, J) The observed group separation by sample material type before drift correction was significantly reduced after drift correction. (K) The strong reduction of the technical variability over all 4 runs after drift corrections shows how well the RF-based algorithm reduced technical noise. All plots are based on 164 known metabolites and all samples from the measurement run per cohort ($n_1 = 16$, $n_2 = 33$, $n_3 = 118$, n4 = 109). A, C, D, G, H used *log10*-transformed. B, E, F, I, J used *log10*-transformed, drift corrected data.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. S3. Correlation of selected metabolites with clinical parameters in the training cohort. (A) Volcano plot of all pairwise Pearson correlations of all 164 metabolites (drift corrected, log_{10} -transformed data) versus 43 clinical parameters highlighting strong (absolute R > 0.5, grey vertical lines) and significant (p_{BH} < 0.05, grey horizontal line) correlations. Based on training cohort (n = 169). (B) Heatmaps with hierarchical clustering of the respective metabolite vs. clinical parameter. Pearson correlations were filtered to keep only rows and columns with at least

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

one sig. correlation. All pairwise Pearson correlation results can be found in Supplementary Data 1. Uric acid and creatinine were measured as metabolite and were part of routine hematology. Accordingly, these parameters show the strongest, most significant correlations. (C) Overview of all investigated numeric clinical parameters correlated in (A, B) with all metabolites, listing their short names, explanations and units.



Fig. S4. Data split has little impact on performance of RF, XGBoost or Ratios in predicting PH. The data was split 70:30 into trainings (n = 163, solid line) and validation set (n = 70, dashed line) balanced by age, BMI, sex and class, data was log₁₀-transformed. (A) ROC plots of RF (green) and XGBoost (blue) trained with data from training cohort predicting class in validation cohort based on 153 metabolites and 95% confidence intervals marked by ribbons. (B) The ROC plots of the three best FFA/lipid-ratios and 95% confidence intervals marked by ribbons. (C) Plot of model performance metrics specificity, sensitivity and balanced accuracy for RF, XGBoost, and the three best FFA/lipid-ratios when based on either training (circles) or validation (diamonds) cohorts only or all available data (squares).



 $ratio3 = \frac{FFA20:1 + FFA18:2 + FFA17:0 + FFA16:1 + FFA15:0}{PC38:6 + PC36:4 + LPC18:1}$

Fig. S5. A quarter million of FFA/lipids-ratios could diagnose PH. (A-F) The histograms summarize the AUCs of the ROC analysis for all 240 570 FFA/lipid-ratios in each data type and split. The histogram of ROC analysis performance AUC for all possible FFA/lipid-ratios exhibits a tight distribution showing that all ratios performed similarly good. (G-I) Direct comparison of AUCs between the trainings and validation cohorts. (A, B, G, H) ROC analysis within the training cohort (cohort 1, 2, 3 n = 169) of the original split by centers benchmarked against the (D, E, G, H) validation cohort (cohort 4 n = 64). (C, I) ROC analysis within the trainings set (n = 163) of the 70:30 split (balanced by age, BMI, sex and class PH/DC/HC) and the (F, I) validation set (n = 70). (A, D, G) are based

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17.23289772; this version posted November 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

on drift *log10*-transformed, drift corrected data while (**B**, **C**, **E**, **F**, **H**, **I**) are based on *log10*-transformed data. (**J**) The histogram of the calculated technical error ratio for each ratio exhibits a tight distribution around 5% total technical relative variability showing. The grey vertical line marks the maximally acceptable technical variability cut-off for measurement methods in clinical routine laboratories. (**K**) The AUC from (**A**) and (**B**) are very similar to each other, confirming that the drift correction only slightly influences ROC analysis. (**L**) The AUC from (**B**) and (**C**) are very similar to each other, confirming that the split by center delivers very similar results to the 70:30 balanced split. Axes were scaled to exclude empty regions in (**A-I**, **K**, **L**), especially for AUC < 0.6 which have no to very little predictive value. (**M**) Overview of top performing ratios for the original split by center with and without drift correction. The equations for the in both datasets top 3 ratios are given.

440



Fig. S6. Survival analysis of covariates age, sex and BMI and linear correlation of top three RATIOs with clinical parameters. (A) Cox HR analysis for survival since baseline and the 95% confidence interval with statistical significance coded as not significant (ns); * p < 0.05; ** p < 0.01; *** p < 0.001. Higher age alone and in the trifactor model was a significant risk factor while BMI and sex were slightly elevated but never significant. (B) Kaplan–Meier curves of survival times since baseline by age, sex or BMI. Age and BMI cut-offs were optimized with maxstat. (C) Heatmaps with hierarchical clustering of pairwise Pearson correlations of the top three RATIOs (*log10*-transformed data) versus 43 clinical parameters. All PH patients with survival times and both clinical scores were included (n = 91). All pairwise Pearson correlation results can be found in Supplementary Data 1.



Fig. S7. Survival analysis of established clinical risk factors and top metabolites. Kaplan–Meier curves analyzing survival times since baseline either for all PH patients or PH patients with both clinical scores available (n = 91). The stated cut-off for survival prediction was optimized with maxstat. (A) Survival of PH patients significantly decreases with known clinical risk factors such as higher WHO FC classes, lower 6MWD, higher NT-pro-BNP levels, and higher uric acid levels.

Supplementary Tables 443

444 445 Table S1: Subject characteristics with medians ± 95% confidence intervals within measurement runs of the training cohort

	run 1		run 2				run 3		
	HC (n=8)	PH (n=8)	HC (n=12)	DC (n=9)	PH (n=12)		HC (n=45)	DC (n=21)	PH (n=52)
Age at sampling, y	57.0±8.8	58.5±9.0	70.5±10.8	56.0±10.1	63.0±9.3		58.0±2.6	60.0±5.7	66.5±3.7
Female:male (ratio)	7:1 (7:1)	7:1 (7:1)	11:1 (11:1) 7:2 (3.5:1)	11:1 (11:1)		26:19 (1.4:1)	13:8 (1.6:1)	30:22 (1.4:1)
BMI kg/m²	22.6±2.7	24.8±3.4	25.8±3.0	30.7±5.5	25.5±3.5		24.1±1.0	22.5±3.2	25.7±1.3
Diagnosis since y	-	3.0±5.9	-	-	6.0±4.0		-	8.0±2.1	0.0±1.1
Pulmonary hemodynamics	Pulmonary hemodynamics from RHC								
mPAP (mmHg) mean pulmonary arterial pressure	-	45.0±7.7	-	-	41.5±5.8		-	22.0±0.8 [#]	41.0±3.1
PAWP (mmHg) pulmonary arterial wedge pressure	-	10.0±4.2	-	-	5.5±1.7		-	9.5±0.3 [#]	10.0±1.6
CO (L/min) cardiac output	-	4.1±1.6	-	-	4.3±0.8		-	3.9±0.4 [#]	4.6±0.5
CI (L/min/m²) cardiac index	-	2.3±0.7	-	-	2.5±0.5		-	2.4±0.3 [#]	2.6±0.2
PVR (WU) pulmonary vascular resistance	-	8.3±3.7	-	-	8.9±3.1		-	3.2±0.3 [#]	6.0±1.2
RAP (mmHg) right arterial pressure	-	5.0±3.8	-	-	5.0±2.4	<u>.</u>	-	5.0±1.1 [#]	7.0±1.5
Clinical data									
6MWD (m) 6-min walk distance	-	338±96	-	-	431±149		-	454±50	317±32
WHO FC world health organisation functional class	-	3.0±0.6	-	-	3.0±0.5		-	2.0±0.3	3.0±0.2
FEV1 (% predicted) forced expiration 1 s	-	83.0±16.5	-	-	82.5±12.9		-	51.5±12	68.5±6.7
FVC (% predicted) forced vital capacity	-	90.9±18.0	-	-	97.6±14.8		-	63.8±8.2	78.0±6.5
FEV1/FVC (% predicted)	-	73.3±6.0	-	-	78.3±6.5		-	56.3±10.3	73.2±3.9
TLC (% predicted)	-	95.7±12.5	-	-	103.1±9.4		-	103.0±13.2	92.0±5.2
DLCO cSB (% predicted) single-breath CO diffusing capacity, hemoglobin corrected	-	69.5±8.4	-	-	65.4±9.5		-	49.6±9.6	56.4±8.2
DLCO cVA (% predicted) CO diffusing capacity alveolar volume, hemoglobin corrected	-	74.6±14.1	-	-	60.6±20.8		-	70.0±9.6	71.0±7.8
RDW (%) red cell distribution width	-	15.5±1.1	-	-	14.4±0.9		-	14.0±0.9	15.7±1.0
NT-proBNP (pg/mL)	-	508±1197	-	-	263±1122		-	98±47	1100±1112.2
Uric acid (mg/dL)	-	5.7±1.4	-	-	5.7±1.6		-	5.0±0.6	6.2±0.7
Creatinine (mg/dL)	-	0.92±0.17	-	-	1.02±0.19		-	0.80±0.11	1.04±0.17
Bilirubin total (mg/dL)	-	0.61±0.25	-	-	0.57±0.26		-	0.40±0.16	0.70±0.17

446 [#]based on 4 patients, not representative

	ID	Age	Sex		ID	Age	Sex	mPAP
1 2 3 4 5 0 6 7 8 9 10	1	[50-59]	male		1	[30-39]	female	50
	2	[70-79]	female		2	[30-39]	female	88
	3	[50-59]	female		3	[18-29]	female	56
	[30-39]	male		4	[18-29]	female	69	
	5	[18-29]	female	ID A LI	5	[50-59]	male	66
	6	[50-59]	male	IГАП	6	[18-29]	male	74
	7	[18-29]	male		7	[50-59]	male	65
	8	[70-79]	female		8	[30-39]	female	69
	9	[50-59]	female		9	[40-49]	male	96
	10	[50-59]	female		10	[18-29]	female	65

447 Table S2: Characteristics of patients with IPAH and healthy donors used for laser capture-microdissection of PA.

Table S3: Primers used to assess the expression of listed genes. Gene name, PubMed Nucleotide accession number used for primer design, forward and reverse primer sequences and the size of the PCR product (in bp) 4 are given. All primers were designed so that the PCR product span at least one exon-exon junction.

Gene	Forward primer	Reverse primer	Product size (bp)
SLC25(A5)	GTTGTCGCAGGTGGACTTCT	CCTTACCCTCACAACCTGGC	71
GPAT1	CTGCTAGGGCAGCAGCG	TGCTGGGATGAAAGTTCTTCTGT	108
GPAT2	CTTCCCTTGAGCAGTCCACG	GCCATGAGAGCCTCACACCA	87
AGPAT1	ACAGAGACACAGCCATCCG	CAAATCCATTCTGGCCACCTCAG	102
LIPIN2	TCTCCGCCTTCCACAGAGAA	CTGCTTAGACGGGGGCAAACA	98
DGAT1	CAACTACCGTGGCATCCTG	TTCTCCAGAAATAACCGGGC	72

452

453

454 Table S4: Characteristics of the hPASMC and hPAEC donors used for in vitro studies.

	ID	Age	Sex		ID	Age	Sex
hPASMC	1	[30-39]	male		1	[50-59]	male
	2	[50-59]	female	hPAEC	2	[40-49]	female
	3	[30-39]	male		3	[50-59]	female
	4	[30-39]	female		4	[50-59]	male
	5	[18-29]	female				
	6	[30-39]	male				